Boehringer Ingelheim is continuing to explore its newfound enthusiasm for eye health, penning a $1 billion biobucks pact with ...

Boehringer Ingelheim partners with Re-Vana Therapeutics to innovate long-acting eye disease treatments, enhancing patient care and compliance.

Re-Vana Therapeutics develops products to improve the delivery of drugs for chronic eye diseases, increasing the quality of ...

Re-Vana Therapeutics has entered a partnership and licence agreement with Boehringer Ingelheim for the development of eye therapies.

Boehringer Ingelheim and Re-Vana Therapeutics, a U.S. and UK based developer of ocular therapeutics and drug delivery ...

Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, ...

Re-Vana’s drug delivery technology is designed to release treatments over a 6- to 12-month period, with the goal of reducing ...

Queens University spin-out Re-Vana Therapeutics has agreed a $1bn deal with biopharma giant Boehringer Ingelheim.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable ...

Boehringer Ingelheim and Re-Vana Therapeutics, a USA and UK based developer of ocular therapeutics and ocular drug delivery ...

ArisGlobal, an AI-first technology company and creator of LifeSphere®, today announced significant momentum in the first half of 2025, driven by continued product innovation via LifeSphere® NavaX™, ...